AstraZeneca PLC (LON:AZN) Insider Pascal Soriot Buys 20,000 Shares

AstraZeneca PLC (LON:AZN) insider Pascal Soriot purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was purchased at an average cost of £102.03 ($128.58) per share, with a total value of £2,040,600 ($2,571,644.61).

AstraZeneca Stock Down 3.1 %

Shares of AZN stock opened at GBX 9,978 ($125.75) on Friday. The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89. The firm’s 50-day moving average is £117.03 and its 200-day moving average is £121.32. The stock has a market cap of £154.66 billion, a price-to-earnings ratio of 3,167.62, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca PLC has a 52-week low of GBX 9,461 ($119.23) and a 52-week high of £133.88 ($168.72).

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a £140 ($176.43) target price on shares of AstraZeneca in a research note on Thursday, November 7th. Berenberg Bank reaffirmed a “buy” rating and issued a £150 ($189.04) target price on shares of AstraZeneca in a research note on Monday, September 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($138.63) target price on shares of AstraZeneca in a research note on Tuesday, September 3rd. Finally, Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of £104.12 ($131.22).

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.